Exjade: improved bioavailability for new presentation

Exjade (deferasirox) is now available as a film-coated tablet, a strength-adjusted formulation of deferasirox with higher bioavailability than Exjade dispersible tablets.

As a result of its improved bioavailability the dose for the film-coated tablet is 30% lower than that of the dispersible tablet. Accordingly, the film-coated tablet is available in lower strengths than the dispersible tablet (90mg, 180mg and 360mg versus 125mg, 250mg and 500mg, respectively).

As a risk mitigation measure to avoid medication errors, and in agreement with the European Medicines Agency, Novartis plans to discontinue Exjade dispersible tablets in the UK at the end of June 2017.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Statin prescribing 'commonly breaching NICE guidance'

Statin prescribing 'commonly breaching NICE guidance'

Prescribing of suboptimal statin regimens is 'extremely...

New contraindication for co-cyprindiol

New contraindication for co-cyprindiol

Cyproterone-containing medicines are now contraindicated...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

GPs demand clarity on flu vaccination plans for 2020/21

GPs demand clarity on flu vaccination plans for 2020/21

GPs say they are struggling to plan flu vaccine orders...